Boosted by a fresh $30 million tranche of funding, Tarveda will start phase 2 trials of its lead drug for neuroendocrine tumors and small cell lung cancer…

Johnson & Johnson has unveiled a clutch of deals intended to grow its presence in the microbiome sector.

Arix Bioscience has filed to raise £100 million in an IPO to bankroll investments in 10 to 15 early-stage biotechs.

ARCH Ventures, Versant and Cardinal Partners have come together in a $50 million Series A raise and launch for upstart Vividion.

Two years after being founded, Cambridge, Massachusetts, upstart Cue Biopharma has raised $26 million to help advance its work using biologics to target T cell…

As Donald Trump is sworn into office today, we look at what the next 100 days and indeed the next four years could mean for the biopharma industry through his…

Women’s health biotech ObsEva has set the terms for an IPO that could net it in the region of $87 million.

The J.P. Morgan event is known as the event for biotech and the investor community and, although typically aimed at generalists, bio journalists are always on…

As his inauguration nears, Donald Trump has interviewed an eclectic mix of candidates for his pick as National Institutes of Health (NIH) chief.

Venture Capital